[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589941":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":29,"locations":38,"responsibleParty":64,"collaborators":10,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":10,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":10,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HCC patients with PVTT.",null,"58 HCC patients with PVTT.",[13],"Diagnostic Test: Prothrombin induced by vitamin K absence II (PIVKA-II)",{"label":15,"type":10,"description":16,"interventionNames":17},"HCC Patients without PVTT.","58 HCC Patients without PVTT.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Prothrombin induced by vitamin K absence II (PIVKA-II)","Serum PIVKA-II level will be measured in HCC patients with and without PVTT.",[15,9],[25],{"name":26,"affiliation":27,"role":28},"Rania M Elkafoury, MD","Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University","STUDY_DIRECTOR",[30,34],{"name":26,"role":31,"phone":32,"phoneExt":10,"email":33},"CONTACT","+201004672358","rania.elkafoury@med.tanta.edu.eg",{"name":35,"role":31,"phone":36,"phoneExt":10,"email":37},"Nabila A Elgazzar, MD","00201288585733","nabilaelgazzar@med.tanta.edu.eg",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Tanta University Hospitals","RECRUITING","Tanta","Gharbyea","31516","Egypt","EG",{"type":48,"coordinates":49},"Point",[50,51],31.00192,30.78847,{"lat":51,"lon":50},[54,58,60,62],{"name":55,"role":31,"phone":56,"phoneExt":10,"email":57},"Dina H Ziada, MD, head of department","00201117109990","dina.ziada@med.tanta.edu.eg",{"name":26,"role":59,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":61,"role":59,"phone":10,"phoneExt":10,"email":10},"Madonna M Fahmy, MD",{"name":35,"role":63,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":63,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Rania Mamdouh Elkafoury","Lecturer of Tropical medicine","100589941","pivka-ii-for-predicting-portal-vein-thrombosis-in-hepatocellular-carcinoma-100589941",false,"NCT06960954","PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma","Prothrombin Induced by Vitamin K Absence II (PIVKA-II) Serum Level as a Predictor for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma Patients.","Inclusion Criteria:\n\n* Male or female patients older than 18 years.\n* Patients with confirmed HCC with or without PVTT (Diagnosed by two imaging modalities or one imaging modality with elevated serum alpha fetoprotein or liver biopsy).\n\nExclusion Criteria:\n\n* Prior locoregional therapy or liver transplantation.\n* Patients on vitamin K, vitamin K antagonists or antibiotics.\n* Patients with cholestasis.\n* Patients with renal insufficiency.\n* Patients with other malignancies.\n* Unwilling to participate in our study.","ALL","18 Years",{"count":77,"type":78},116,"ESTIMATED","OBSERVATIONAL","The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients.\n\nResearchers will compare PIVKA-II serum levels in HCC patients with PVTT and without PVTT.\n\nParticipants will undergo history-taking, clinical examination, laboratory investigations, PIVKA-II serum level, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, and Triphasic CT abdomen with contrast or MRI to evaluate tumor site, size, number, and presence of PVTT (a filling defect in the portal vein or its branch to distinguish PVTT or thrombus).",[82,83],"Hepato Cellular Carcinoma (HCC)","Portal Vein Tumour Thrombosis",[85,86,87],"PIVKA-II","Portal vein tumor thrombosis","Hepatocellular carcinoma","2025-04-29",{"date":90,"type":91},"2025-05-07","ACTUAL",{"date":93,"type":91},"2025-01-15",{"date":95,"type":78},"2025-12-31",{"name":5,"class":6},1]